ArticleResearch in pharmaceutical sciences2021
Effects of
Article in Research in pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 15 citations in OpenAlex.
- The effect ofResearch in pharmaceutical sciences · 2024Article
- The therapeutic value of thiazole and thiazolidine derivatives in Alzheimer's disease: a systematic literature review.Research in pharmaceutical sciences · 2024Review
- Enhancing the Antioxidant Activity of Alginic Acid Extracted from Sargassum Angustifolium Brown Algae Based on Optimizing the Extraction.Advanced biomedical research · 2024Article
- From kitchen to clinic: Pharmacotherapeutic potential of common spices in Indian cooking in age-related neurological disorders.Frontiers in pharmacology · 2022Review
- Betaine attenuates oxidative stress and cognitive dysfunction in an amyloid β-induced rat model of Alzheimer's disease.Research in pharmaceutical sciencesArticle
- Effects of hydroalcoholic, methanolic, and hexane extracts of brown algaeResearch in pharmaceutical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeAlzheimer's disease is a progressive brain disorder that is thought to be triggered EXPERIMENTAL APPROACH: In this study, FINDINGS/
resultsAdministration of scopolamine significantly impaired memory performance in both memory paradigms. In the passive avoidance test (PAT) model, PN at doses up to 100 mg/kg and CZ at doses up to 400 mg/kg did not significantly alter the memory impairment induced by scopolamine. The combination of these two plant extracts did not change the PAT parameters. In the object recognition test (ORT) model, however, administration of 100 mg/kg CZ alone and a combination of PN (50 mg/kg) with CZ (400 mg/kg), significantly increased the recognition index ( CONCLUSION AND IMPLICATIONS: Two plant extracts when administered alone or in combinations affected the memory performance differently in two memory paradigms. In the PAT model, the extracts did not show any memory improvement, in ORT, however, some improvements were observed after plant extracts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.